Key result
Non-invasive VNS is suggested as an adjuvant therapy to reduce COVID-19 burden and severity.
Why the study?
Specific treatment for COVID-19, an acute-infective inflammatory-immunological condition, is still lacking, and non-invasive vagal nerve stimulation has been proposed to reduce disease severity.
Does non-invasive vagal nerve stimulation reduce disease severity in patients with COVID-19?
Does non-invasive vagal nerve stimulation reduce disease severity in patients with COVID-19?
Vagal nerve stimulation is proposed as a potential non-pharmacological adjuvant therapy to attenuate inflammation and reduce disease severity in COVID-19.
Hypothesis-generating for non-invasive VNS in COVID-19; prospective RCTs required before clinical consideration.
COVID-19 is a major healthcare problem worldwide. Unfortunately, specific treatment for COVID-19, which is an acute-infective inflammatoryimmunological condition, is still lacking. Vagal nerve stimulation (VNS) has been reported to attenuate inflammation both in experimental models and in human beings. The development non-invasive VNS, a non-pharmacological adjuvant therapy, has recently been tried to reduce the burden of COVID-19 and the disease severity. VNS has been suggested as an adjuvant treatment for the management of COVID-19. Read more...
No takes yet. Share an insight, caveat, or question.
G. K. Pal (2022) conducted a review in COVID-19. Vagal nerve stimulation (VNS) was evaluated. Vagal nerve stimulation has been suggested as a non-pharmacological adjuvant therapy to reduce the burden and severity of COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: